Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.33 |
| ▸ | DDX3X | O00571 | 1/20 | 0.33 |
| ▸ | CHAT | P28329 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4436537 | 0.92 | MYC (0.40) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL2187405 | 0.82 | MYC (0.41) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL5071261 | 0.80 | TTR (0.38) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL2778003 | 0.80 | MYC (0.41) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL10914937 | 0.78 | CA2 (0.50) | CDK2 | |
| SCHEMBL31618334 | 0.78 | ELANE (0.44) | TDP1KDM4EPOLBL3MBTL1GAA | |
| SCHEMBL8664478 | 0.78 | MYC (0.41) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| Potassium Ion SCHEMBL28703143 | 0.77 | RAD51 (0.35) | NR4A1PGAM1GAA | |
| SCHEMBL29664068 | 0.75 | TSHR (0.55) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL150335 | 0.75 | TSHR (0.55) | MYCTSHRSMN1; SMN2TTRFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4155376-A1 | SURFACE TREATMENT METHOD FOR SEMICONDUCTOR SUBSTRATE, AND SURFACE TREATMENT AGENT COMPOSITION | Central Glass Company, Limited (JP) | 2023-03-29 | — | — | EP | claimed |
| EP-4155375-A1 | SURFACE TREATMENT METHOD FOR SEMICONDUCTOR SUBSTRATES, AND SURFACE TREATMENT AGENT COMPOSITION | Central Glass Company, Limited (JP) | 2023-03-29 | — | — | EP | claimed |
| CN-109428110-B | Rechargeable lithium battery | 三星SDI株式会社 | 2022-04-29 | — | — | CN | claimed |
| CN-111943874-A | Aryl naproxen derivative high-valence iodine compound and preparation method and application thereof | 五邑大学 | 2020-11-17 | — | — | CN | claimed |
| CN-111095656-A | Lithium secondary battery | 三星SDI株式会社 | 2020-05-01 | — | — | CN | claimed |
| EP-3451433-B1 | RECHARGEABLE LITHIUM BATTERY | SAMSUNG SDI CO LTD (KR) | 2020-04-22 | — | — | EP | claimed |
| EP-3281941-B1 | PROCESS FOR PREPARING 2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ZENTIVA KS (CZ) | 2019-07-24 | — | — | EP | claimed |
| CN-109428110-A | Lithium rechargeable battery | 三星SDI株式会社 | 2019-03-05 | — | — | CN | claimed |
| EP-2031031-B1 | Use of a latent acid for improving adhesion | SIKA TECHNOLOGY AG (CH) | 2011-07-13 | — | — | EP | claimed |
| EP-2031031-A1 | Use of a latent acid for improving adhesion | Sika Technology AG (CH) | 2009-03-04 | — | — | EP | claimed |
| US-20260018421-A1 | SUBSTRATE PROCESSING METHOD, AND SUBSTRATE MANUFACTURING METHOD | CENTRAL GLASS CO LTD (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20250343040-A1 | SUBSTRATE PROCESSING METHOD AND SUBSTRATE PRODUCTION METHOD | CENTRAL GLASS CO LTD (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-4535405-A1 | SUBSTRATE PROCESSING METHOD AND SUBSTRATE PRODUCTION METHOD | Central Glass Company, Limited (JP) | 2025-04-09 | — | — | EP | disclosed |
| EP-4535406-A1 | SUBSTRATE PROCESSING METHOD, AND SUBSTRATE MANUFACTURING METHOD | Central Glass Company, Limited (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250066621-A1 | COMPOSITION FOR FILM FORMATION AND METHOD FOR MANUFACTURING SUBSTRATE | CENTRAL GLASS COMPANY, LIMITED (JP) | 2025-02-27 | — | — | US | disclosed |
| US-20020128469-A1 | Beta-lactam production | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2002-09-12 | — | — | US | disclosed |
| EP-1169324-A1 | BETA-LACTAM PRODUCTION | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000063214-A1 | BETA-LACTAM PRODUCTION | BIOCHEMIE GESELLSCHAFT M B H (AT) | 2000-10-26 | — | — | WO | disclosed |
| US-5847218-A | Sulfonium salts and chemically amplified positive resist compositions | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| US-5705702-A | REACTING AN ARYL GRIGNARD REAGENT WITH THIONYL CHLORIDE, THEN WITH TRIORGANOSILYL SULFONATE OR TRIORGANOSILYLHALIDE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260018421-A1 | SUBSTRATE PROCESSING METHOD, AND SUBSTRATE MANUFACTURING METHOD | ESPL1, SMS, SGMS1 | MYC 2032/4885TSHR 2961/4885SMN1; SMN2 295/4885 |
| US-20020128469-A1 | Beta-lactam production | MRPL21, COASY, Q6ZSR9 | MYC 1115/4885TSHR 4041/4885SMN1; SMN2 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.